Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504021 · ClinicalTrials.gov registry record · NA
Family Meeting Study for End Stage Renal Disease
A NA study, sponsored by Mark A. Lumley.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT02504021: Completed NA study, sponsored by Mark A. Lumley.
NCT02504021 is a NA study that has completed, run by Mark A. Lumley. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02504021, a NA study, has completed, sponsored by Mark A. Lumley.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
A randomized clinical trial for patients with end stage renal disease in which a family consultation condition is compared against a treatment as usual control condition on the hospital readmissions after 1 month as the primary outcome variable.
Primary Outcome
Were patients readmitted to the hospital within 1 month of their initial discharge?
Interventions
- BEHAVIORAL Family Consultation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-10 |
| Phase | NA |
What the finished NCT02504021 record still lists
NCT02504021 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Family Consultation is the first listed.
NCT02504021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02504021 about?
NCT02504021 is a clinical study titled "Family Meeting Study for End Stage Renal Disease". A randomized clinical trial for patients with end stage renal disease in which a family consultation condition is compared against a treatment as usual control condition on the hospital readmissions after 1 month as the primary outcome variable.
What is the current status of trial NCT02504021?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2015-07. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02504021?
The interventions under investigation include: Family Consultation (BEHAVIORAL).
Who is sponsoring clinical trial NCT02504021?
This trial is sponsored by Mark A. Lumley, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02504021's enrollment target sits among peer trials
120 762nd of 2000 higher than 1,198 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia